Nutrition & mushrooms 2016

UV-treated mushrooms and vitamin D status: a meta-analysis of 6 RCTs — the effect appears only with baseline deficiency

A meta-analysis of 6 RCTs: overall, UV mushrooms did **not** raise 25(OH)D (P=0.12, I²=87%). But splitting by geography revealed the point: in 3 European RCTs with baseline deficiency (~39 nmol/L) the +15.2 nmol/L gain was significant; in 3 US trials with adequate baseline (~81) — zero. Plus confirmed D2→D3 displacement.

J Nutr 2016. Effect of Ultraviolet Light-Exposed Mushrooms on Vitamin D Status: LC-MS/MS Reanalysis of Biobanked Sera from an RCT and a Systematic Review plus Meta-Analysis (PMID 26865648).

Rationale

The RCT data on UV mushrooms and 25(OH)D were "limited and mixed". The authors pooled all eligible RCTs and added their own LC-MS/MS reanalysis of sera — the gold standard for vitamin-D metabolites instead of the less accurate immunoassay.

Methods

  • Systematic search of Ovid MEDLINE, EMBASE, Cochrane CENTRAL → 6 RCTs of UV-exposed mushrooms reporting serum 25(OH)D.
  • Reanalysis of biobanked sera from one RCT by LC-MS/MS for separate 25(OH)D2 and 25(OH)D3.
  • Meta-analysis using weighted mean difference (WMD).

Results

  • Across all 6 RCTs: 25(OH)D did not rise significantly (P=0.12), with high heterogeneity (I²=87%).
  • 3 European RCTs (baseline ~38.6 nmol/L — deficiency): +15.2 nmol/L gain, significant (P=0.03).
  • 3 US RCTs (baseline ~81.5 nmol/L — adequate): no effect (P=0.83).
  • By vitamin form: UV mushrooms raise 25(OH)D2 but lower 25(OH)D3 — displacement confirmed.

Conclusions

UV-treated mushrooms improve vitamin D status only where it was low (European populations with deficiency); with adequate baseline there is no effect. The heterogeneity is explained precisely by differing baseline status and geography.

Caveats

  • The key framing for readers: "mushroom vitamin D" is a tool against deficiency, not a universal supplement. Expecting a boost where none is missing is futile.
  • The D2→D3 displacement shows why total 25(OH)D is the right endpoint, not 25(OH)D2 alone.
  • High heterogeneity (I²=87–88%) is an honest signal: real doses, mushroom species and UV protocols differed between trials; "any UV mushrooms" is too broad a category.
  • The LC-MS/MS reanalysis showed immunoassays can distort separate D2/D3 accounting — a methodological detail that matters when reading older RCTs.